

# Table of Contents



*Over 1,000 corporations in 70 countries are relying on our market intelligence, expert analysis, and strategic insight, critical to the development and implementation of effective business, R&D and marketing programs.*

[www.LeadingMarketResearch.com](http://www.LeadingMarketResearch.com)

[www.VPGMarketResearch.com](http://www.VPGMarketResearch.com)

[reports@vpgcorp.com](mailto:reports@vpgcorp.com)

+1 212 564 2838

## Table of Contents

### **I. Introduction**

### **II. Worldwide Market Overview**

### **III. Major Product Development Opportunities**

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

### **IV. Design Criteria for Decentralized Testing Products**

### **V. Alternative Market Penetration Strategies**

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

### **VI. Potential Market Entry Barriers and Risks**

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

### **VII. Worldwide Market and Technology Overview**

#### **A. Cancer Statistics and Etiology**

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

## Table of Contents (continued)

### B. Major Current and Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
  - Abl/abl-bcr
  - AIB1
  - BCL-2
  - BRCA1
  - CD44
  - C-fos
  - C-myb
  - C-myc
  - CYP-17
  - Erb-B
  - HPC1
  - N-myc
  - P40
  - P51
  - P53
  - PIK3CA
  - PTI-1
  - Ras
  - Reg

## **Table of Contents** (continued)

- Sis
- Src and others
- 28. Polypeptide Growth Factors
  - Basic Fibroblast Growth Factor
  - Beta-TGF
  - Cachectin (TNT)
  - Calmodulin
  - ECFR
  - Nerve Growth Factor (NGF)
  - Epidermal Growth Factor (EGF)
  - Ornithine Decarboxylase
  - Transferrin
  - Transforming Growth Factor-Alpha
- 29. Ectopic Hormones
- 30. Colony Stimulating Factors
- 31. Lymphokines
  - Alpha-Interferon
  - B Cell Growth Factors
  - B Cell Growth Factor (BCGF)
  - Gamma-Interferon
  - Interleukin-1 (IL-1)
  - Macrophage Activating Factor
- 32. Immunohistochemical Stains
- 33. Emerging Tumor Markers
  - N-Acetylglucosamine
  - Actin
  - Alpha-Actin
  - Antineuronal Antibodies
  - 7B2
  - B72.3
  - Bax
  - BCD-F9
  - BLCA-4
  - Blood Group Antigens A,B,H
  - CA 50
  - CA 72-4/TAG-72
  - CA 195
  - CA-242
  - CA-549
  - CAM 26
  - CAR-3
  - Cathepsin-D
  - Chromogranin A and B
  - Cluster 1 Antigen
  - Cluster-5/5A Antigen
  - CTA
  - CU18
  - DR-70

## Table of Contents (continued)

- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92

## **Table of Contents** (continued)

- Proliferative Index, Ki-67
- P<sub>x</sub>
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen and others

### C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

### D. Current and Emerging Cancer Diagnostic Technologies

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
  - a. Chronic Myelogenous Leukemia (CML)
  - b. Acute Myeloid Leukemia (AML)
  - c. Acute Lymphoblastic Leukemia (ALL)
  - d. Malignant Lymphomas Lymphoid Malignancies
  - e. Chronic Lymphocytic Leukemia (CLL)
  - f. Solid Cancers
  - g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies

### E. Personal Testing

## **Table of Contents** (continued)

### **VIII. Country Analysis**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Dynamics, Trends, Size and Growth
  - Volume Forecasts by Test and Market Segment
  - Sales Forecasts by Test and Market Segment
  - Major Supplier Sales and Market Shares

### **IX. Competitive Profiles**

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:

- Abbott
- Affymetrix
- Beckman Coulter/Danaher/Cepheid
- Becton Dickinson
- bioMerieux
- Bio-Rad
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujifilm Wako
- Fujirebio
- Grifols
- Hologic
- Leica Biosystems
- PerkinElmer
- Qiagen
- QuidelOrtho
- Roche
- Siemens Healthineers
- Takara Bio
- Thermo Fisher and others.